Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: Patterns of fractionation study of radiobiology

Withers, H. Rodney; Peters, Lester J.; Taylor, Jeremy M. G.; Owen, Jean B.; Morrison, William H.; Schultheiss, Timothy E.; Keane, Thomas J.; O’Sullivan, Brian; Dyk, Jacob Van; Gupta, Nirmal Kumar; Wang, C.C.; Jones, Christopher U.; Doppke, Karen P.; Myint, S.; Thompson, Myra; Parsons, James T.; Mendenhall, William M.; Dische, Stanley; Aird, Edwin; Henk, J.M.; Bidmead, M.; Svoboda, V.; Chon, Yun; Hanlon, Alexandra L.; Peters, Theresa L.; Hanks, Gerald E.

doi:10.1016/0360-3016(95)00229-r

Cited by 118 publications

(41 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, here we provide evidence that changes in both CM and L parallel each other and are detectable early during IMRT suggesting a similar etiology/ physiopathology and validating the hypothesis that they actually represent ''consequential'' late reactions (21). As such, this would fit the radiobiological behavior of acute reactions (22) and changes could potentially be monitored during treatment in order to minimize their late effects. That we observed changes over baseline in both CM and L in 91.6% and 100% of patients, respectively, probably reflects the higher mean doses planned in our study.…”

Section: Discussionmentioning

confidence: 53%

Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer

Ricchetti

McNutt

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 53%

Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer

Ricchetti

McNutt

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…In most patients in the present study, the prescribed dose was 50 Gy in 25 fractions over 5 weeks, because a considerable total dose is required due to the radioresistance of the relapsed tumor and because a small fraction size is required to prevent severe late radiation injury. [7][8][9] Although the number of patients in the present study was not large in comparison with previous reports, the stages of relapsed non-small-cell lung cancer and the prescribed radiation doses were relatively uniform. [10][11][12][13][14] Several suggestive findings in our study may contribute to the future study of relapsed non-small-cell lung cancer after radiation therapy.…”

Section: Discussionmentioning

confidence: 58%

Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy

et al. 2005

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis demonstrated that increasing the total dose and the dose per fraction of radiation but not the length of the treatment increased the likelihood of developing muscle injury. 23 In a recent review of radiation recall, the vast majority of cases were attributed to anthracyclines and taxanes (69%). Radiation recall reactions most often developed in the skin but occasionally were noted in the muscle, lungs, bowel, esophagus, central nervous system, and vulva.…”

Section: Manifestations Of Radiation Recall Reactions Attributed To Gmentioning

confidence: 99%

Gemcitabine‐related radiation recall preferentially involves internal tissue and organs

Friedlander

Bansal

Schwartz

et al. 2004

Cancer

View full text Add to dashboard Cite

Radiation recall refers to inflammatory reactions triggered by cytotoxic agents and develops in previously irradiated areas. Most reactions develop cutaneously. The most common chemotherapeutic agents implicated are anthracyclines and taxanes. Gemcitabine, a nucleotide analog, recently was implicated in several cases.The authors performed a literature search using PubMed and the search terms "gemcitabine" and "radiation recall" to find prior cases of radiation recall attributed to gemcitabine. These cases were compared with those attributed to anthracyclines and taxanes. The literature search found 12 cases of radiation recall caused by gemcitabine. The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to gemcitabine and were discussed in the current study to 13. Approximately 70% of the cases manifested as inflammation of internal organs or tissues and 30% manifested as a dermatitis or mucositis. This finding differs from other common agents, in which 63% of the radiation recall events are reported to manifest as a dermatitis. Compared with anthracyclines and taxanes, the interval from the completion of radiation therapy to the initiation of chemotherapy is less for gemcitabine (median time of 56 days for gemcitabine, compared with 218 days for the taxanes and 646 days for doxorubicin). The majority of radiation recall reactions attributed to gemcitabine are reported to affect internal tissue or organs. In contrast, other common agents for the most part trigger cutaneous inflammation. The development of internal tissue inflammation is reportedly correlated with a shorter interval from the time of completion of radiation therapy to the initiation of chemotherapy.

show abstract

Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: Patterns of fractionation study of radiobiology

Cited by 118 publications

References 14 publications

Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer

Volumetric Change of Selected Organs at Risk During IMRT for Oropharyngeal Cancer

Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy

Gemcitabine‐related radiation recall preferentially involves internal tissue and organs

Contact Info

Product

Resources

About